Slate of new drugs added to Pharmaceutical Benefits Scheme


Australians confronting illnesses ranging from breast cancer to spinal muscular atrophy and a painful inflammatory condition will soon enjoy cheaper access to treatments.

Eosinophilic oesophagitis (EoE) causes difficulty swallowing and chest discomfort and affects an estimated 2000 people nationally.

Instead of paying up to $5000 a year for EoE medication budesonide, Health Minister Greg Hunt has announced patients will spend $42.50 per script, or $6.80 with a concession card, after its listing on the Pharmaceutical Benefits Scheme.

Gastroenterologist Sanjay Nandurkar from Melbourne’s Eastern Health says treatment is crucial to prevent permanent damage to the oesophagus.

“Due to the complexity of EoE, it can take up to six years from symptom onset to diagnose the disease in adults, and may result in anxiety and/or depression in some patients,” he said.

“If left untreated, 30 to 50 per cent of people living with EoE are at risk of food suddenly becoming stuck in the oesophagus (food impaction), which may require removal in the emergency department.”

A similar PBS listing for the treatment of spinal muscular atrophy (SMA) in young children and pre-symptomatic patients will save Australian families more than $2.5 million annually.

Antibody drug sacituzumab govitecan will also save triple negative breast cancer patients about $80,000 per course of treatment.

Help for opioid addicts

Mr Hunt says the new listings are among 2900 the government has approved since 2013 and continue its commitment to ensuring Australians can access treatments without huge out of pocket costs.

Buprenorphine, sold as Buvida and Australia’s first long-acting treatment for opioid dependence, is now also available to more patients following an extension of its indication on the PBS.

SMART Recovery Australia welcomed the news on Sunday.

“We are fortunate to live in a country that invests in supporting this community through national support programs and holistic support,” executive director Ryan McGlaughlin said.

Mr McGlaughlin said the extension would also mean improved flexibility for patients with more time to find work or study and contribute to society.


Source: Read More

We’ve Already Come Too Far To End This Now.

Subscribe To Our Weekly Newsletter

Get notified about new articles